Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147329 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00147329 is a Phase 2 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT00147329, a Phase 2 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis. MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein (AFP). Adults normally have very small amounts of AFP in their bloodstream. However, during pregnancy, AFP levels in both the mother and the fetus are much higher than normal. It has been observed that some women with psoriasis and other autoimmune diseases such as rheumatoid arthritis have fewer symptoms during pregnancy, particularly during the third trimester. At this time, the levels of AFP in the blood of the mother and fetus are the highest. This observation led Merrimack to begin examining MM-093 as a potential treatment for psoriasis. This study is designed to further test the safety and effectiveness of MM-093 in patients with psoriasis.
Interventions
- DRUG MM-093
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147329
The ClinicalTrials.gov registry entry for NCT00147329 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MM-093 is the first listed.
NCT00147329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00147329 about?
NCT00147329 is a clinical study titled "Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis". Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis. MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein (AFP). Adults normally have very small amounts of AFP in t...
What is the current status of trial NCT00147329?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00147329?
The interventions under investigation include: MM-093 (DRUG).
Who is sponsoring clinical trial NCT00147329?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.